학술논문
Durvalumab +/− Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase III POSEIDON Study. (German)
Document Type
Article
Author
Source
Pneumologie; 2022 Supplement, Vol. 76, pS48-S48, 1p
Subject
Language
German
ISSN
09348387